Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
11 hedge funds and large institutions have $3.34M invested in Kiromic BioPharma, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
263% more capital invested
Capital invested by funds: $919K → $3.34M (+$2.42M)
57% more funds holding
Funds holding: 7 → 11 (+4)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$1.82M |
| 2 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
+$444K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$102K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$98.5K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$58.3K |
| 2 |
APWA
Atlas Private Wealth Advisors
Matawan,
New Jersey
|
-$17K |
| 3 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$13.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1CM
1
1492 Capital Management
Milwaukee,
Wisconsin
| $1.74M | +$1.82M | +6,198 | New |
|
|
ZCA
2
Zeke Capital Advisors
Berwyn,
Pennsylvania
| $442K | -$13.5K | -46 | -3% |
|
|
RAM
3
Redmond Asset Management
Henrico,
Virginia
| $425K | +$444K | +1,514 | New |
|
|
IP
4
Intellectus Partners
San Francisco,
California
| $359K | +$28.4K | +97 | +8% |
|
|
5
Citadel Advisors
Miami,
Florida
| $203K | +$98.5K | +336 | +87% |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $98K | +$102K | +347 | New |
|
7
BlackRock
New York
| $48K | +$15.5K | +53 | +45% |
|
8
UBS Group
Zurich,
Switzerland
| $16K | – | – | – |
|
9
Morgan Stanley
New York
| $13K | +$13.8K | +47 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$58.3K | -199 | -99% |
|
|
APWA
11
Atlas Private Wealth Advisors
Matawan,
New Jersey
| – | -$17K | -67 | Closed |
|
|
HI
12
Harbour Investments
Madison,
Wisconsin
| – | +$293 | +1 | New |
|
KRBP Hedge Fund Activity: Q1 2021 in Review
11 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q1 2021, worth a combined $3.34M — up 263% from $919K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KRBP positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was 1492 Capital Management, opening a new position worth an estimated $1.82M. The largest seller was Tower Research Capital (TRC), cutting an estimated $58.3K.
- 11 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q1 2021, up from 7 in Q4 2020.
- Funds reported $3.34M of Kiromic BioPharma, Inc. Common Stock stock for Q1 2021, up 263% quarter-over-quarter.
- 5 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q1 2021 and 1 closed out, a net change of +4 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q1 2021 was 1492 Capital Management, an estimated $1.82M added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q1 2021 was Tower Research Capital (TRC), an estimated $58.3K sold.
Based on aggregated 13F filings for Q1 2021.